secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001193125-25-120261
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q1 net revenue $11.3M; net loss narrows to $16.3M; targets 1H 2025 profitability
--------------------------------------------------------------------------------

- PEMGARDA net product revenue of $11.3M in Q1 2025, down from $13.8M in Q4 2024 due to sales force transition; re-acceleration seen in Q2 2025.
- Net loss of $16.3M ($0.14 per share) vs $43.5M ($0.38) a year ago; R&D expenses fell to $10.6M from $31.2M.
- Cash and equivalents $48.1M as of March 31 2025; secured $30M non-dilutive term loan facility with Silicon Valley Bank in April 2025.
- FDA declined EUA expansion request for PEMGARDA as a treatment in Feb 2025 but provided potential near-term pathway for VYD2311.
- VYD2311 Phase 1 data read-out (potency, half-life, safety) anticipated later in Q2 2025; pipeline expansion into RSV and measles underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/0001193125-25-120261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/d66861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-120261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer